Cutaneous Squamous Cell Carcinoma

Oncology·MeSH: Carcinoma, Merkel Cell

16 drugs in development·10 companies·16 clinical trials

Drug Pipeline by Phase

Approved(3)

Drug	Company
unloxcyt	Fortress Biotech Inc. (FBIO)
unloxcyt	Fortress Biotech Inc. (FBIO)
unloxcyt	Checkpoint Therapeutics, Inc. (CKPT)

Phase 3(3)

Drug	Company
cemiplimab+fianlimab fixed dose combination	REGENERON PHARMACEUTICALS, INC. (REGN)
fdc fianlimab+cemiplimab	REGENERON PHARMACEUTICALS, INC. (REGN)
regn15505+cemiplimab	REGENERON PHARMACEUTICALS, INC. (REGN)

Phase 2(7)

Drug	Company
cemiplimab	Replimune Group, Inc. (REPL)
incb099280	Incyte Corp. (INCY)
LN-145	ENANTA PHARMACEUTICALS INC (ENTA)
LN-145	Filana Therapeutics Inc. (FLNA)
LN-145	Merus N.V. (MRUS)
rp1	Replimune Group, Inc. (REPL)
vidutolimod	CHECKMATE PHARMACEUTICALS, INC. (CMPI)

Phase 1(3)

Drug	Company
cemiplimab	REGENERON PHARMACEUTICALS, INC. (REGN)
cosibelimab	Checkpoint Therapeutics, Inc. (CKPT)
gen-011	GENOCEA BIOSCIENCES, INC. (GNCA)

BioSniper tracks 16 drugs in development for Cutaneous Squamous Cell Carcinoma across 10 companies.

There are 16 clinical trials targeting Cutaneous Squamous Cell Carcinoma tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.